Sep 4, 2025 06:13AM
Aug 7, 2025 04:05PM
May 1, 2025 04:05PM
Mar 3, 2025 06:41AM
Feb 27, 2025 04:05PM
Jan 13, 2025 08:00AM
Nov 15, 2024 08:06AM 89bio Inc. (ETNB) Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH
Nov 15, 2024 08:05AM
Oct 15, 2024 08:30AM
Aug 6, 2024 06:41AM
May 22, 2024 04:05PM
May 14, 2024 08:00AM
May 10, 2024 06:57AM
Apr 17, 2024 04:05PM 89bio Inc. (ETNB) Appoints Martin Babler to its Board
Apr 17, 2024 04:05PM
Mar 27, 2024 08:00AM
Mar 27, 2024 08:00AM
Mar 12, 2024 08:04AM
Mar 12, 2024 08:00AM
Mar 8, 2024 04:05PM
Mar 5, 2024 04:05PM 89bio to Participate in the Leerink Partners Global Biopharma Conference
Feb 29, 2024 04:05PM
Feb 5, 2024 04:05PM
Dec 19, 2023 04:05PM
Dec 12, 2023 07:30AM
Dec 7, 2023 07:02AM
Dec 7, 2023 07:00AM
Dec 6, 2023 04:36PM 89bio Inc. (ETNB) Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Dec 6, 2023 04:36PM
Dec 4, 2023 07:06AM
Dec 4, 2023 07:00AM
Nov 27, 2023 08:02AM
Nov 27, 2023 08:00AM
Nov 21, 2023 04:01PM
Nov 13, 2023 05:34AM 89bio (ETNB) Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin
Nov 12, 2023 12:15PM
Nov 8, 2023 04:01PM
Sep 21, 2023 08:00AM
Sep 21, 2023 08:00AM
Aug 9, 2023 04:01PM
Jun 24, 2023 05:05AM
Jun 24, 2023 05:01AM Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-
May 23, 2023 08:03AM
May 23, 2023 08:00AM
May 4, 2023 04:05PM
Mar 22, 2023 04:02PM
Mar 22, 2023 12:23PM
Mar 22, 2023 10:38AM
Mar 22, 2023 07:00AM 89bio (ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved High Statistical Significance on Both Primary Histology Endpoints
Mar 22, 2023 07:00AM

322,090 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All